The value of STEAP1, C-myc and P63 Immuno-expression in differentiation of prostatic carcinoma from its mimickers

Submit Date: 10-07-2019 Revise Date: 13-07-2019 Accept Date: 20-07-2019 ABSTRACT Background: Prostatic adenocarcinoma is the 2 nd most common cancer in males. It is important to differentiate between prostatic adenocarcinoma and its benign mimickers with novel and reliable immunohistochemical markers for early diagnosis of prostatic adenocarcinoma, (6-transmembrane epithelial antigen of prostate (STEAP1), C-myc and basal cell marker P63 can be helpful in distinguishing prostatic adenocarcinoma from benign lesions. The aim of this study is to diagnose prostatic adenocarcinoma and differentiate it from its benign mimickers using STEAP1, C-myc and P63 immunoexpression and toevaluate the role of STEAP1 overexpression in prostate cancer initiation and progression. Methods: Retrospective cross-sectional study was conducted on 20 cases of prostatic adenocarcinoma, 8 cases of high grade prostatic intraepithelial neoplasia (HGPIN) and 18 cases of benign prostatic mimickers. All lesions were submitted for STEAP1, C-myc and P63 immunohistochemistry and the results were correlated with clinicopathological and histopathological parameters. Results: P63, STEAP1 and C-myc showed highly significant difference in expression in prostatic adenocarcinoma in relation to its benign mimickers (p-value<0.001). STEAP1 immunoexpression was significantly associated with Gleason score, grade grouping and perineural invasion of prostatic adenocarcinoma (p-value <0.05). Positive STEAP1 and Cmyc expression along with negative P63 showed high sensitivity (80.0%, 85.0% and 95.0%) respectively and considerable specificity (86.9%, 73.1% and 96.2%) respectively for differentiating between prostatic adenocarcinoma and its benign mimickers. Conclusion: STEAP1, C-myc and P63 immunoexpression was helpful in differentiation between prostatic adenocarcinoma and benign mimickers. STEAP1 may have a valuable prognostic role in prostatic adenocarcinoma.

• Publication year

  2019

• Venue

  Zagazig University Medical Journal

• Publication date

  2019-07-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.21608/ZUMJ.2019.14012.1282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer: diagnostic criteria and role of immunohistochemistry

  2018cited by this paper
• Six Transmembrane Epithelial Antigen of Prostate (STEAP1) Immunohistochemical Expression in Neoplastic and Non-Neoplastic Epithelial Lesion of Prostate

  2018cited by this paper
• Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression

  2018cited by this paper
• Benign mimics of prostatic adenocarcinoma

  2018cited by this paper
• MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer

  2017cited by this paper
• Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians

  2017cited by this paper
• Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

  2016cited by this paper
• Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics

  2016cited by this paper
• Histopathological features of intra‐ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63

  2016cited by this paper
• Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.

  2016cited by this paper
• The evolution of cancer registration in Egypt: From proportions to population-based incidence rates

  2015cited by this paper
• Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.

  2015cited by this paper
• ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.

  2015cited by this paper
• Expression of STEAP1 and STEAP1B in prostate cell lines, and the putative regulation of STEAP1 by post-transcriptional and post-translational mechanisms

  2014cited by this paper
• An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers.

  2014cited by this paper
• Immunohistochemical Biomarkers of Prostatic Carcinoma

  2014cited by this paper
• 4FISH-IF, a Four-Color Dual-Gene FISH Combined with p63 Immunofluorescence to Evaluate NKX3.1 and MYC Status in Prostate Cancer

  2013cited by this paper
• STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma

  2013cited by this paper
• Expression of Caveolin-1,P63 and CK34βE12 in prostate cancer and its clinical significance

  2012cited by this paper
• Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma

  2012cited by this paper
• Cancer statistics for african americans

  1992cited by this paper

• No citing papers are available for this paper.